Trademark Search  /  ERADEC

ERADEC

● Live · Pending

U.S. federal trademark · Serial No. 99517928 · Reg. No. 88281799

Mark
ERADEC
Status
Pending
Serial Number
99517928
Registration No.
88281799
Filing Date
October 29, 2025
Registration Date
May 21, 2026
Class(es)
Class 005, Class 042

Owner

Shanghai ATTEC Biotechnology Co., Ltd.
22 · Shanghai, CN

Goods & Services

Medicines for human purposes for the treatment of cancer, neoplastic diseases, metabolic diseases, neurologic disorder, neurodegenerative diseases, autoimmune diseases, and immunological diseases; Pharmaceutical preparations for the treatment of cancer, neoplastic diseases, metabolic diseases, neurologic disorder, neurodegenerative diseases, autoimmune diseases, and immunological diseases; Chemico-pharmaceutical preparations for the treatment of cancer, neoplastic diseases, metabolic diseases, neurologic disorder, neurodegenerative diseases, autoimmune diseases, and immunological diseases; Drugs for medical purposes, namely, small molecule drugs for targeted protein degradation; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer, neoplastic diseases, metabolic diseases, neurologic disorder, neurodegenerative diseases, autoimmune diseases, and immunological diseases via targeted protein degradation

Technical research in the field of targeted protein degradation; Research and development of new products for others; Chemical analysis; Chemical analysis services; Chemical research; Bacteriological research and development; Biological research; Medical and scientific research, namely, conducting clinical trials for others; Medical research and development of therapeutics; Pharmaceutical development

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "ERADEC" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.